Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: treat-to-target

Lupus Classification Criteria Expanded; Treat-to-Target Approach Gains Support

  |  

Rheumatologists at the California Rheumatology Alliance 10th Annual Medical & Scientific Meeting in San Francisco outline disease classification criteria, treat-to-target approach to lupus

Statin Guideline Eliminates Cholesterol Treat-to-Target Strategy for Managing Atherosclerotic Cardiovascular Risk

  |  

Experts question how to apply the new American College of Cardiology and American Heart Association guidelines in patients with rheumatic disease and call for further validation of the risk assessment algorithm

Kidney Biopsy in Lupus Nephritis

  |  

SAN DIEGO—As part of a Nov. 14 session on lupus nephritis at ACR Convergence 2023, Simone Appenzeller, MD, PhD, shared perspectives on the importance of biopsy to inform its diagnosis, prognosis and treatment, with an emphasis on childhood disease. Prompt diagnosis and treatment of lupus nephritis is perhaps even more important for children than for…

Optimizing DMARD Use in Older Adults with Rheumatoid Arthritis

Devyani Misra, MD, MS, & Jiha Lee, MD, MHS  |  

SAN DIEGO—Older adults with rheumatoid arthritis (RA) comprise two groups: those who have lived with diagnosed RA since an early age (young-onset RA) and those who have new-onset RA diagnosed at an older age (≥65 years), known as late-onset RA or, formerly, as elderly onset RA.1 Individuals with late-onset RA have more acute and systemic…

Study: Most Patients with PMR Aren’t Getting Steroid-Sparing Agents in First 2 Years

Katie Robinson  |  

A minority of patients with polymyalgia rheumatica (PMR) who were new to rheumatology practice were prescribed steroid-sparing agents through two years of follow-up. This is according to a large, U.S.-based cohort study, published in Arthritis Care & Research, which also found that nearly two-thirds of the patients remained on glucocorticoids beyond one year.1 “Our study…

Management Updates for a Spectrum of Systemic Autoinflammatory Diseases

  |  

SAN DIEGO—As part of a panel on systemic autoinflammatory diseases (SAIDs) at a Nov. 15 scientific session of ACR Convergence 2023, Sivia Lapidus, MD, shared context and insights on the therapeutic management of patients with these conditions. The Spectrum of SAIDs SAIDs encompass a broad swath of individually rare disorders driven by innate immune responses…